Secondary analysis of the MA.32 trial (3649 non-diabetic patients with high-risk breast cancer): BMI and blood metabolic factors did not identify subgroups benefiting from metformin vs placebo; some interactions suggested possible adverse effects at lower levels.
Secondary analysisn = 3,649
Goodwin et al. Exploration of body mass index and circulating metabolic factors as predictors of metformin benefit in the Canadian Cancer Trials Group MA.32